| Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy F Baert, D Drobne, A Gils, NV Casteele, S Hauenstein, S Singh, S Lockton, ... Clinical Gastroenterology and Hepatology 12 (9), 1474-1481. e2, 2014 | 167 | 2014 |
| Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease D Drobne, P Bossuyt, C Breynaert, T Cattaert, NV Casteele, ... Clinical Gastroenterology and Hepatology 13 (3), 514-521. e4, 2015 | 151 | 2015 |
| Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives K Papamichael, W Afif, D Drobne, MC Dubinsky, M Ferrante, PM Irving, ... The lancet Gastroenterology & hepatology 7 (2), 171-185, 2022 | 81 | 2022 |
| Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy U Kopylov, J Hanzel, C Liefferinckx, D De Marco, N Imperatore, N Plevris, ... Alimentary pharmacology & therapeutics 52 (1), 135-142, 2020 | 66 | 2020 |
| Down‐regulation of microRNAs of the miR‐200 family and up‐regulation of Snail and Slug in inflammatory bowel diseases — hallmark of epithelial−mesenchymal … N Zidar, E Boštjančič, M Jerala, N Kojc, D Drobne, B Štabuc, D Glavač Journal of cellular and molecular medicine 20 (10), 1813-1820, 2016 | 64 | 2016 |
| Acute biliary pancreatitis: detection of common bile duct stones with endoscopic ultrasound B Štabuc, D Drobne, I Ferkolj, A Gruden, J Jereb, G Kolar, V Mlinaric, ... European journal of gastroenterology & hepatology 20 (12), 1171-1175, 2008 | 53 | 2008 |
| Success and safety of high infliximab trough levels in inflammatory bowel disease D Drobne, T Kurent, S Golob, P Svegl, P Rajar, S Terzic, M Kozelj, ... Scandinavian journal of gastroenterology 53 (8), 940-946, 2018 | 48 | 2018 |
| Peak concentrations of ustekinumab after intravenous induction therapy identify patients with Crohn’s disease likely to achieve endoscopic and biochemical remission J Hanžel, J Zdovc, T Kurent, N Sever, K Javornik, K Tuta, M Koželj, ... Clinical Gastroenterology and Hepatology 19 (1), 111-118. e10, 2021 | 43 | 2021 |
| Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease D Drobne, T Kurent, S Golob, P Švegl, P Rajar, J Hanžel, M Koželj, ... Alimentary Pharmacology & Therapeutics 49 (7), 880-889, 2019 | 42 | 2019 |
| Impact of infliximab and cyclosporine on the risk of colectomy in hospitalized patients with ulcerative colitis complicated by cytomegalovirus—a multicenter retrospective study U Kopylov, K Papamichael, K Katsanos, M Waterman, A Bar-Gil Shitrit, ... Inflammatory bowel diseases 23 (9), 1605-1613, 2017 | 41 | 2017 |
| Endoscopic postoperative recurrence in Crohn’s disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab: a real-world … H Yanai, A Kagramanova, O Knyazev, J Sabino, S Haenen, GJ Mantzaris, ... Journal of Crohn's and Colitis 16 (12), 1882-1892, 2022 | 34 | 2022 |
| Pathology of fibrosis in Crohn's disease—contribution to understanding its pathogenesis N Zidar, C Langner, M Jerala, E Boštjančič, D Drobne, A Tomažič Frontiers in medicine 7, 167, 2020 | 31 | 2020 |
| Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective L Jonaitis, S Marković, K Farkas, L Gheorghe, Ž Krznarić, R Salupere, ... BMC proceedings 15, 1-6, 2021 | 28 | 2021 |
| Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease J Hanžel, N Sever, I Ferkolj, B Štabuc, N Smrekar, T Kurent, M Koželj, ... United European Gastroenterology Journal 7 (6), 741-749, 2019 | 28 | 2019 |
| Dose optimisation for loss of response to Vedolizumab—pharmacokinetics and immune mechanisms B Ungar, K Malickova, J Hanžel, M Abu Arisha, S Paul, C Rocha, ... Journal of Crohn's and Colitis 15 (10), 1707-1719, 2021 | 27 | 2021 |
| OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis MT Arias, N Van de Casteele, D Drobne, M Ferrante, I Cleynen, V Ballet, ... Journal of Crohn's and Colitis, S5, 2012 | 26 | 2012 |
| Anti-TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors I Cleynen, W Van Moerkercke, M Juergens, V Ballet, D Drobne, ... Gut 59 (suppl 3), A1, 2010 | 24 | 2010 |
| A Population pharmacokinetic and exposure–response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis E Dreesen, W Kantasiripitak, I Detrez, S Stefanović, S Vermeire, ... Inflammatory Bowel Diseases 26 (4), 570-580, 2020 | 19 | 2020 |
| Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn’s disease J Hanžel, M Koželj, AŠ Hlastec, T Kurent, N Sever, J Zdovc, N Smrekar, ... European Journal of Gastroenterology & Hepatology 33 (1S), e831-e836, 2021 | 16 | 2021 |
| Crohn's disease: infliximab trough levels and CRP during infliximab-immunomodulator combination treatment are associated with clinical outcome after immunomodulator withdrawal D Drobne, PJ Bossuyt, C Breynaert, NV Casteele, G Compernolle, ... Gastroenterology 5 (140), S-62, 2011 | 13 | 2011 |
